CLINICAL LAB MEDICARE COMPETITIVE BIDDING OPPOSED IN OCT. 31 LETTER FROM INDUSTRY/MEDICAL GROUPS; PROJECT TARGETS CHEMISTRY, HEMATOLOGY, SEROLOGY TESTS
This article was originally published in The Gray Sheet
Executive SummaryMedicare competitive bidding for clinical laboratory services should be delayed for at least two years, a group of laboratory and medical associations say in an Oct. 31 letter to Nancy-Ann Minn DeParle, acting administrator of the Health Care Financing Administration.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.